source
- FDA approves Orca Bio's T cell therapy Tregzi to lower transplant complications in blood cancer patientsThe U.S. Food and Drug Administration has granted approval to Orca Bio's T cell therapy aimed at improving outcomes for patients undergoing blood cancer transplants. The therapy, named Tregzi, is…
- BridgeBio secures up to $1 billion in preferred equity as United Therapeutics invests $140 million to acquire ThymmuneBridgeBio Pharma announced that Sixth Street Partners and HealthCare Royalty will provide up to $1 billion in preferred equity to support its upcoming product launches. The financing is structured…